Biological agents targeting on pro-inflammatory cytokines

研究成果: Review article査読

1 被引用数 (Scopus)

抄録

Biological agents targeting on pro-inflammatory cytokines are developed, and provide a great impact on the medical management of rheumatoid arthritis (RA). Particularly, biologics against tumor necrosis factor(TNF) can not only induce great clinical improvement, but also halt structural damage on the joints. Now chimeric anti-TNFalpha monoclonal antibody, infliximab, full human anti-TNFalpha monoclonal antibody, adalimumab, and TNF receptor II (p75) -IgGFc fusion protein, etanercept, are widely used in the inflammatory disorders including RA. This review article shows the characteristics of these anti-TNF biologics on RA, and summarizes the efficacy as well as the safety of the agents.

本文言語English
ページ(範囲)1601-1606
ページ数6
ジャーナルNippon rinsho. Japanese journal of clinical medicine
63
9
出版ステータスPublished - 2005 9
外部発表はい

ASJC Scopus subject areas

  • 医学(全般)

フィンガープリント

「Biological agents targeting on pro-inflammatory cytokines」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル